Business Wire

Market Survey by TSUNO Group Reveals “Rice Bran Oil” Market in Japan Is Expanding Under COVID-19 Pandemic

1.3.2021 13:35:00 EET | Business Wire | Press release

Share

TSUNO Group (HQ: Wakayama, Japan https://www.tsuno.co.jp) surveys the sales figure of edible vegetable oils and rice bran oil in Japan. (Data of The Nikkei 64 major chains stores and 461 stores in Japan March to May result based on total sales).
As a result, the market of Rice Bran Oil for household use has expanded by 42% compared to the previous year.
While the vegetable oil sales increased by 11% from previous year, rice bran oil and sesame oil sales grew by 42% during a state of emergency in Japan.
The rapid expansion of these two oils could be explained by a rise in people’s health-consciousness under COVID-19 pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005397/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TSUNO brand rice bran oils sized from 180g to 1500g. Full nutrients from rice bran are contained. Rice Bran Oil has strong anti oxidant effect and its healthy and goes well with any kind of dishes from dressing to deep fries. (Photo: Business Wire)

[Insights]
The growth of edible vegetable oil market for household use due to the increase in the number of people staying at home.
After the declaration of state of emergency from the Government of Japan, , the number of people who cook at home increased from various reasons : work from home, closure of schools and restaurants.
The rise in demand for edible vegetable oils is one of the key points to consider the rapid expansion of rice bran oil market.

The rise in demand for healthy and versatile vegetable oils.
Rice bran oil and sesame oil are highly versatile for daily use. The demand for rice bran oil has expanded because it’s resistant to oxidation and Japanese people could have a good impression on its healthy aspect.

Sales of TSUNO bran rice bran oil expanded.
The TSUNO brand rice bran oil ranges from 180g to 1500g.
Usually, 500g size is the most popular however 1500g sales has increased in this pandemic period.
Rice bran oil is recognized as a healthy oil that can be used any kind of dishes in daily use.
A survey conducted in 2019 for TSUNO’s EC site members in Japan shows that rice bran oil is used in fried foods, stir-fried foods, simmered foods, and dressings including Japanese-style Chinese and western style foods.

About TSUNO Group Co., Ltd.

TSUNO Group aims at contributing to health, beauty and environment protection through investigation of rice bran.
We operate three business, all of them are utilizing Rice bran that is generated from rice, one of the world’s three major grains.
Our products are used by wide range of customers, from general household, food industry, medical industry to cosmetic industry.
We have businesses with approximately 40 countries all over the world.
Since its foundation, TSUNO group has been prioritized quality control, environment and safety as the basis of all corporate activities, including research and development, production, distribution and sales.
Believing “environmentally friendly products bring people’s beauty and health”, we proactively continue and keep on improving our sustainable corporate activities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mai Sakaue
TSUNO Group Co., Ltd.
+81-80-4245-7991
pr@tsuno.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye